Novel anti-infective medical device

世界上每年有超过1亿人使用导尿管。然而，这些设备是世界上最常见的医疗保健感染-导管相关性尿路感染(CAUTI)的根本原因。CAUTI严重到需要抗生素治疗的程度，影响了24%的长期患者，其中~70%的致病菌表现出抗药性，在英国每年导致约2100人死亡。CAUTIs通常采用长期的抗生素疗程治疗，但这会导致致命的抗菌素耐药性细菌的传播。Clean Blue Limited正在开发解决方案：一种在不使用任何药物的情况下防止细菌定居的导管，以减少目前对抗生素治疗的依赖和随后发生AMR的风险。这项新技术的成功开发和应用可以改善病人的护理，为NHS挽救生命和数百万英镑，并在抗击抗药性细菌方面开辟新的战线

Over 100 million people use urinary catheters in the world every year. However, these devices are the root cause for the most common healthcare infection in the world, catheter-associated urinary tract infections (CAUTIs). CAUTIs serious enough to require antibiotic treatment affect 24% of long-term patients, of which ~70% of the bacteria responsible show antimicrobial resistance, resulting in ~ 2,100 deaths in the UK annually. CAUTIs are typically treated by long-term courses of antibiotics but this contributes to the spread of deadly antimicrobial resistant bacteria. Clean Blue Limited is developing the solution: a catheter that prevents colonisation of bacteria without using any pharmaceuticals in order to reduce the current dependency on antibiotic treatment and the subsequent risk of AMR occurrence. The successful development and application of this new technology could improve patient care; save lives and millions of pounds for the NHS; and open up a new front in the fight against antibiotic resistant bacteria